Medtronic Q4 Earnings Call Highlights

1 week ago 9

MarketBeat

Wed, June 3, 2026 astatine 8:04 AM CDT 8 min read

Key Points

Interested successful Medtronic PLC? Here are 5 stocks we similar better.
Medtronic posted beardown fiscal Q4 and full-year results, with gross of $9.8 cardinal successful the 4th and $36.4 cardinal for the year, some supra expectations. Management said it was the company’s strongest top-line show successful a decade, driven by maturation crossed cardiac ablation, diabetes, medical-surgical, and neuroscience businesses.
Cardiac ablation was the standout maturation engine, arsenic Cardiac Ablation Solutions surged 78% worldwide and pulsed tract ablation jumped 145% globally. Medtronic said its CAS concern is present annualizing astatine much than $2 cardinal and expects continued outgrowth versus the broader marketplace successful fiscal 2027.
The institution guided for continued maturation successful fiscal 2027, forecasting integrated gross maturation of 6.75% to 7.25% and adjusted EPS of $5.90 to $6.00. The outlook includes the recently separated MiniMed diabetes concern and factors successful an expected $250 cardinal tariff deed to outgo of goods sold.

3 Reasons Analysts Love DexCom

Medtronic (NYSE:MDT) reported what executives described arsenic its strongest top-line show successful a decade, arsenic maturation successful cardiac ablation, diabetes, medical-surgical products and prime neuroscience platforms helped thrust fiscal fourth-quarter and full-year results supra expectations.

Chairman and Chief Executive Officer Geoff Martha said the institution generated $9.8 cardinal successful gross successful the 4th fourth of fiscal 2026, up 9.9% connected a reported ground and 6.6% organically. For the afloat fiscal year, gross was $36.4 billion, up 8.4% reported and 5.8% organically. Adjusted net per stock were $1.55 for the 4th and $5.53 for the year.

→ Best Buy’s AI Laptop Boost Sparks Hope for a BBY Turnaround

Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity

“These results correspond the compounding interaction of deliberate choices we've made crossed strategy, operations, and culture,” Martha said, citing execution successful foundational businesses specified arsenic cardiac bushed management, cranial and spinal technologies, and surgical products, arsenic good arsenic advancement successful higher-growth platforms.

Cardiac Ablation Remains a Key Growth Driver

Cardiac Ablation Solutions was a standout successful the quarter, with Martha reporting 78% worldwide maturation and an further 8 points of U.S. share. Pulsed tract ablation grew 145% globally, supported by the company’s Sphere-9 exertion and Affera platform.

→ 3 Up-and-Coming Stocks That Could Be the Next NVIDIA

5 Spin-Off Stocks That Could Reward Patient Investors successful 2026

Chief Financial Officer Thierry Piton said the cardiovascular portfolio grew 10% successful the quarter, including 14% successful the U.S. and 7% internationally. Within that segment, CAS grew 78%, including 124% successful the U.S. Piton said the CAS concern is present annualizing astatine much than $2 cardinal successful gross and is connected way to scope $2 cardinal connected a trailing ground successful the archetypal 4th of fiscal 2027.

Read Entire Article